6. SONUÇ VE ÖNERİLER
Sonuç olarak bu çalışmada şiddetli periodontitisi olan hastalarda kanser riskinin toplumda bu yaş ve cinsiyet grubundaki hastalara kıyasla beklenenden daha yüksek olduğunu saptadık. Periodontal patojen bakteriler birçok kanserin patogenezinde riski etkileyen faktörler olabilir. Literatürdeki önceki çalışmalara benzer şekilde periodontitisin erkekte artmış prostat kanseri ve hematolojik kanser riski, kadında ise artmış meme kanseri riski ile ilişkili olduğunu gösterdik. Ciddi periodontitis ile genel kanser riski, spesifik organ kanserleri ve patojen bakterilerin ilişkisini sebep sonuç ilişkisi kapsamında gösterebilmek için prospektif çalışmalara ihtiyaç vardır. Periodontitisin tedavisinin kanser riskini azaltıp azaltmadığına dair çalışmalar, kanser prevansiyonu açısından önemli olacaktır. Son olarak bu bulgularla ağız sağlığı ve ağız hijyeninin kanserden primer korunma önlemi olarak önerilmesi uygun olacağını düşündürmektedir.
7. KAYNAKLAR
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin.
2016;66(1):7-30.
2. Türkiye Cumhuriyeti Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu. Türkiye Sağlık İstatistikleri. Ankara 2017.
3. Moscow JA, Cowan KH. Biology of Cancer. In: Goldman L, Schafer AI, editors.
Cecil Medicine. 24 ed. Philadelphia: Elsevier Saunders; 2012. p. 1184.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation.
Nature. 2008;454(7203):436-44.
5. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373-80.
6. Okada F. Beyond foreign-body-induced carcinogenesis: impact of reactive oxygen species derived from inflammatory cells in tumorigenic conversion and tumor progression. Int J Cancer. 2007;121(11):2364-72.
7. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008;99(5):836-42.
8. Tezal M, Sullivan MA. Chronic periodontitis and the risk of oral cancer. In:
Nielsen FL, editor. Progress in oral cancer research. New York: Nova Science Publishers; 2008. p. 91.
9. Linden GJ, Lyons A, Scannapieco FA. Periodontal systemic associations:
review of the evidence. J Clin Periodontol. 2013;40 Suppl 14:S8-19.
Clin Periodontol. 2013;40 Suppl 14:S1-7.
11. Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT. Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study. Arch Intern Med. 2000;160(18):2749-55.
12. Chambrone L, Pannuti CM, Guglielmetti MR, Chambrone LA. Evidence grade associating periodontitis with preterm birth and/or low birth weight: II: a systematic review of randomized trials evaluating the effects of periodontal treatment. J Clin Periodontol. 2011;38(10):902-14.
13. Demmer RT, Jacobs DR, Jr., Desvarieux M. Periodontal disease and incident type 2 diabetes: results from the First National Health and Nutrition Examination Survey and its epidemiologic follow-up study. Diabetes Care. 2008;31(7):1373-9.
14. Linden GJ, Herzberg MC, working group 4 of the joint EFPAAPw. Periodontitis and systemic diseases: a record of discussions of working group 4 of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol. 2013;84(4 Suppl):S20-3.
15. Hujoel PP, Drangsholt M, Spiekerman C, Weiss NS. An exploration of the periodontitis-cancer association. Ann Epidemiol. 2003;13(5):312-6.
16. Michaud DS, Kelsey KT, Papathanasiou E, Genco CA, Giovannucci E.
Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up Study. Ann Oncol. 2016;27(5):941-7.
17. Arora M, Weuve J, Fall K, Pedersen NL, Mucci LA. An exploration of shared genetic risk factors between periodontal disease and cancers: a prospective co-twin study. Am J Epidemiol. 2010;171(2):253-9.
the associations between chronic periodontitis and the risk of cancer. Int J Clin Oncol. 2016;21(2):219-23.
19. Tezal M, Wactawski-Wende J, Grossi SG, Dmochowski J, Genco RJ.
Periodontal disease and the incidence of tooth loss in postmenopausal women. J Periodontol. 2005;76(7):1123-8.
20. Tezal M, Grossi SG, Genco RJ. Is periodontitis associated with oral neoplasms? J Periodontol. 2005;76(3):406-10.
21. Tezal M, Sullivan MA, Reid ME, Marshall JR, Hyland A, Loree T, et al. Chronic periodontitis and the risk of tongue cancer. Arch Otolaryngol Head Neck Surg.
2007;133(5):450-4.
22. Ahn J, Segers S, Hayes RB. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. Carcinogenesis.
2012;33(5):1055-8.
23. Binder Gallimidi A, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein AM, et al. Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget. 2015;6(26):22613-23.
24. Nakhjiri SF, Park Y, Yilmaz O, Chung WO, Watanabe K, El-Sabaeny A, et al.
Inhibition of epithelial cell apoptosis by Porphyromonas gingivalis. FEMS Microbiol Lett. 2001;200(2):145-9.
25. Ha NH, Woo BH, Kim DJ, Ha ES, Choi JI, Kim SJ, et al. Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties. Tumour Biol.
2015;36(12):9947-60.
connection. Curr Opin Genet Dev. 2010;20(1):65-71.
27. Javed F, Warnakulasuriya S. Is there a relationship between periodontal disease and oral cancer? A systematic review of currently available evidence. Crit Rev Oncol Hematol. 2016;97:197-205.
28. Ren HG, Luu HN, Cai H, Xiang YB, Steinwandel M, Gao YT, et al. Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis.
Ann Oncol. 2016;27(7):1329-36.
29. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect. 2007;13 Suppl 4:3-10.
30. Ford PJ, Gemmell E, Hamlet SM, Hasan A, Walker PJ, West MJ, et al. Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosis. Oral Microbiol Immunol. 2005;20(5):296-302.
31. Vogtmann E, Goedert JJ. Epidemiologic studies of the human microbiome and cancer. Br J Cancer. 2016;114(3):237-42.
32. Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al.
Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis.
2014;33(8):1381-90.
33. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al.
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207-15.
34. Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2016.
gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer.
2016;11:3.
36. Atanasova KR, Yilmaz O. Looking in the Porphyromonas gingivalis cabinet of curiosities: the microbium, the host and cancer association. Mol Oral Microbiol.
2014;29(2):55-66.
37. Perera M, Al-Hebshi NN, Speicher DJ, Perera I, Johnson NW. Emerging role of bacteria in oral carcinogenesis: a review with special reference to perio-pathogenic bacteria. J Oral Microbiol. 2016;8:32762.
38. Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80-6.
39. Schmidt J, Jentsch H, Stingu CS, Sack U. General immune status and oral microbiology in patients with different forms of periodontitis and healthy control subjects. PLoS One. 2014;9(10):e109187.
40. Cifcibasi E, Ciblak M, Kiran B, Badur S, Firatli E, Issever H, et al. The role of activated cytotoxic T cells in etiopathogenesis of periodontal disease: does it harm or does it heal? Sci Rep. 2015;5:9262.
41. Freudenheim JL, Genco RJ, LaMonte MJ, Millen AE, Hovey KM, Mai X, et al.
Periodontal Disease and Breast Cancer: Prospective Cohort Study of Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2016;25(1):43-50.
42. Soder B, Yakob M, Meurman JH, Andersson LC, Klinge B, Soder PO.
Periodontal disease may associate with breast cancer. Breast Cancer Res Treat.
2011;127(2):497-502.
43. Bertrand KA, Shingala J, Evens A, Birmann BM, Giovannucci E, Michaud DS.
Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. Int J Cancer. 2016.
ADI, SOYADI:
DOĞUM TARİHİ ve YERİ:
ÖMER DİZDAR 1977 - İSTANBUL HALEN GÖREVİ: DOÇENT DOKTOR
YAZIŞMA ADRESİ: HACETTEPE ÜNİVERSİTESİ KANSER ENSTİTÜSÜ, PREVANTİF ONKOLOJİ AD.
TELEFON: 0 312 305 4330
E-MAIL: omer.dizdar@hacettepe.edu.tr 2. EĞİTİM
YILI DERECESİ ÜNİVERSİTE ÖĞRENİM ALANI
2000 LİSANS HACETTEPE
ÜNİVERSİTESİ TIP FAKÜLTESİ
TIP FAKÜLTESİ
2015- YÜKSEK
LISANS HACETTEPE
ÜNİVERSİTESİ SAĞLIK BİLİMLERİ
ENSTİTÜSÜ – KANSER EPİDEMİYOLOJİSİ PROGRAMI
3. AKADEMİK DENEYİM
GÖREV DÖNEMİ ÜNVAN BÖLÜM ÜNİVERSİTE
2000-2005 ARAŞTIRMA
GÖREVLİSİ
İÇ
HASTALIKLARI
HACETTEPE ÜNİVERSİTESİ TIP FAKÜLTESİ, İÇ HASTALIKLARI AD
2005-2009 ARAŞTIRMA
GÖREVLİSİ MEDİKAL
ONKOLOJİ HACETTEPE ÜNİVERSİTESİ TIP FAKÜLTESİ TIBBİ ONKOLOJİ BD
2009-2011 UZMAN MEDİKAL
ONKOLOJİ
ANKARA ATATÜRK EĞİTİM ARAŞTIRMA HASTANESİ
2011-2014 DOÇENT MEDİKAL
ONKOLOJİ BAŞKENT ÜNİVERSİTESİ TIP FAKÜLTESİ TIBBİ ONKOLOJİ BÖLÜMÜ
2015- DOÇENT PREVANTİF
ONKOLOJİ
HACETTEPE ÜNİVERSİTESİ KANSER ENSTİTÜSÜ
GASTROİNTESTİNAL KANSERLER GASTROİNTESTİNAL KANSERLER
5. YAYINLAR
1. Dizdar O, Arslan C, Altundag K. Advances in PARP inhibitors for the treatment of breast cancer. Expert Opin Pharmacother, 18, 2751-8, (2015)
2. Demirci U, Dızdar O, Cetindag MF, Altınova S, Ozsavran A, Dede DS, Kızılırmak N, Eraslan FA, Yalcın B, Cinkir HY. Radiotherapy concurrent with weekly
gemcitabine after transurethral tumor resection in muscle ınvasive bladder cancer.
J Cancer Res Ther, 11, 704-7, (2015)
3. Serkan AKIN1, Omer DIZDAR2, Lale OZISIK3, Mine D. TANRIOVER3,
Songul KAMISLI2, Mustafa ERMAN2, Mutlu HAYRAN2 Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy. UHOD, 26, 167-72, (2016)
4. Arık Z, Oz M, Dizdar O, Yıldırım ME, Ozgu E, Terzioglu SG, Gungor T.
Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer. UHOD, 26, 110-15, (2016)
5. Arslan C, Dizdar O, Altundag K. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. Expert Opin
Pharmacother, 15, 1643-58, (2014)
6. Ozcan MF, Dizdar O, Dincer N, Balcı S, Guler G, Gok B, Pektas G, Seker MM, Aksoy S, Arslan C, Yalcin S, Balbay MD. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urol Oncol, 31, 1709-15, (2012)
7. Tuna S, Dizdar O, Calis M. The prevalence of usage of herbalmedicines among cancer patients. J BUON, 18, 1048-51, (2013)
8. Kuzan TY, Koca E, Dizdar O, Arslan C, Eren T, Yalcin S, Kucukoztas N, Aksoy S, Rahatli S, Dede DS, Altundag O, Zengin N, Ozyilkan O, Altundag K. Breast